<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03808389</url>
  </required_header>
  <id_info>
    <org_study_id>UGent2018/0623</org_study_id>
    <nct_id>NCT03808389</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation for Parkinson's Disease</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized Clinical Trial Investigating Fecal Microbiota Transplantation for Parkinson's Disease and Its Effect on Symptoms and Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Flanders Institute for Biotechnology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Foundation Flanders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vlaamse Parkinson Liga</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parkili</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson's disease (PD) is the second most common neurodegenerative disorder and due to the&#xD;
      lack of early diagnosis and effective therapy, represents a large burden for our society and&#xD;
      healthcare system. The last years, it became increasingly apparent that non-motor symptoms,&#xD;
      including gastrointestinal dysfunction, precede the onset of the typical PD motor symptoms by&#xD;
      several years. Moreover, emerging evidence suggests that PD, and more specifically the&#xD;
      aggregation of alpha-synuclein, starts in the gut before spreading to the brain.&#xD;
      Additionally, recent microbiome studies consistently showed microbiota differences between PD&#xD;
      patients and healthy controls.&#xD;
&#xD;
      The ultimate goal of this project is to address the impact of gut dysbiosis and the&#xD;
      restoration of gut homeostasis by fecal microbiota transplantation (FMT) on the development&#xD;
      and progression of PD. We will identify PD-specific changes in microbiota composition and gut&#xD;
      inflammation and determine the effect of a 'microbiome-reset' approach through FMT in PD&#xD;
      patients on the identified changes and more importantly on disease symptoms and progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the effects of fecal microbiota transplantation (FMT) on patients with&#xD;
      Parkinson's disease will be investigated in a double-blind, placebo-controlled randomized&#xD;
      clinical trial.&#xD;
&#xD;
      At time of FMT, forty patients will be randomized in a double-blinded fashion to the&#xD;
      treatment arm (healthy donor stool) or placebo arm (own stool). Transplantation will be&#xD;
      performed through nasojejunal administration.&#xD;
&#xD;
      Donors for this study will be recruited from a healthy donor pool who will donate stool after&#xD;
      clearance of a strict inclusion protocol which will assess the presence of any infectious&#xD;
      diseases. Donor stool will be frozen and stored until day of FMT.&#xD;
&#xD;
      Participants will be screened for relevant inclusion and exclusion criteria and will have to&#xD;
      sign an informed consent before admission to the study.&#xD;
&#xD;
      Prior and on a regular basis following the FMT participants will be evaluated through&#xD;
      neurological clinical examination and standardized clinical scoring scales including&#xD;
      MDS-UPDRS, PDQ-39, NMSS and MoCA. Stool samples will be taken regularly and stored at -80°C&#xD;
      for microbiome analysis. Blood will be collected for determining relevant markers. All&#xD;
      participants will also undergo sampling for oral and nasal microbiome. Follow-up will&#xD;
      continue for a total duration of one year.&#xD;
&#xD;
      Prior to FMT, all participants will undergo a colonoscopy to exclude contra-indications for&#xD;
      FMT and to collect mucosa-adherent microbial samples and gastrointestinal tissue biopts. This&#xD;
      colonoscopy will be repeated once, one year following the FMT.&#xD;
&#xD;
      The primary endpoint in this study will be a change in clinical status measured through the&#xD;
      MDS-UPDRS. Additionally, motor and non-motor symptoms will be correlated with serum markers&#xD;
      of inflammation and gut and central nervous system barrier function, microbiota changes and&#xD;
      gastrointestinal biopsy analysis of inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Actual">December 9, 2022</completion_date>
  <primary_completion_date type="Actual">December 9, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>40 patients with Parkinson's disease (Hoehn &amp; Yahr score 2-3) will be randomly allocated (20 vs. 20) to either fecal microbiota transplantation with donor stool or autologous fecal microbiota transplantation (= own stool).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in clinical symptoms as scored on the MDS-UPDRS (Movement Disorder Society - Unified Parkinson's Disease Rating Scale)</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <description>The MDS-UPDRS (Movement Disorder Society - Unified Parkinson's Disease Rating Scale) has four parts: Part I (non-motor experiences of daily living; 13 items), Part II (motor experiences of daily living; 13 items), Part III (motor examination; 33 scores based on 18 items, several with right, left or other body distribution scores) and Part IV (motor complications; 6 items). Each item has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Part III will be clinically scored in an OFF-medication state. Subscales are analyzed separately.&#xD;
References:&#xD;
Goetz, C. et al. Movement Disord 22, 41-47 (2007).&#xD;
Goetz, C. et al. Movement Disord 23, 2129-2170 (2008).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in non-motors symptoms as scored on the Non-motor symptoms scale for Parkinson's disease (NMSS)</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <description>Non-motor symptoms scale for Parkinson's disease (NMSS). Non-motor symptoms are assessed over the last month. Each symptom is scored with respect to:&#xD;
Severity: 0 = None; 1 = Mild: symptoms present but causes little distress or disturbance to patient; 2 = Moderate: some distress or disturbance to patient; 3 = Severe: major source of distress or disturbance to patient.&#xD;
Frequency: 1 = Rarely (&lt;1/wk); 2 = Often (1/wk); 3 = Frequent (several times per week); 4 = Very Frequent (daily or all the time).&#xD;
NMSS contains nine dimensions: cardiovascular (2 items), sleep/fatigue (4 items), mood/cognition (6 items), perceptual problems (3 items), attention/memory (3 items), gastrointestinal (3 items), urinary (3 items), sexual function (2 items), and miscellaneous (4 items).&#xD;
Subscores are calculated through multiplication of frequency x severity. Total score is calculated by adding all subscores, range 0-360.&#xD;
Reference: Chaudhuri, K. R. et al. Mov. Disord. 22, 1901-11 (2007).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life as scored on the Parkinson's Disease Quality of Life Questionnaire (PDQ-39)</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <description>Parkinson's Disease Quality of Life Questionnaire. All 39 questions are coded in the same way: 0 = Never; 1 = Occasionally; 2 = Sometimes; 3 = Often; 4 = Always (or cannot do at all, if applicable).&#xD;
The different dimensions are mobility (10 items), activities of daily living (6 items), emotional well being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items).&#xD;
Each dimension is calculated as a scale from 0 to 100 (0 = no problem at all; 100 = maximum level of problem). Formula for scoring each dimension = (sum of scores of each question in dimension)/ (4 x number of questions in dimension) x 100.&#xD;
The Single Index score: PDQ-SI= summing the eight dimensions and then dividing by eight.&#xD;
Reference: Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. &amp; Hyman, N. Age Ageing 26, 353-7 (1997).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cognition as scored on the Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <description>The Montreal Cognitive Assessment (MoCA) assesses several cognitive domains: short-term memory, visuospatial abilities, executive functions, attention, concentration, working memory, language, orientation to time and place. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.&#xD;
Reference: Nasreddine, Z. et al. J Am Geriatr Soc 53, 695-699 (2005).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a change in required anti-PD symptomatic or levodopa therapy</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gastrointestinal symptoms as assessed by the Rome IV questionnaire</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <description>The Rome IV criteria for functional constipation and irritable bowel syndrome are assessed to evaluate potential change in gastrointestinal symptoms following the fecal microbiota transplantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Treatment group: Donor FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal microbiota transplantation using fecal matter from a healthy donor selected through strict inclusion criteria assessing the presence of any infectious diseases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: Autologous FMT</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Fecal microbiota transplantation using the patient's own fecal matter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Donor FMT</intervention_name>
    <description>Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.</description>
    <arm_group_label>Treatment group: Donor FMT</arm_group_label>
    <other_name>FMT with donor stool</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous FMT</intervention_name>
    <description>Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.</description>
    <arm_group_label>Control group: Autologous FMT</arm_group_label>
    <other_name>FMT with own stool</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Clinical PD diagnosis (MDS criteria)&#xD;
&#xD;
          -  Hoehn &amp; Yahr score of 2-3 in OFF&#xD;
&#xD;
          -  Age of motor symptoms onset &gt; 50 years&#xD;
&#xD;
        Exclusion Criteria for patients:&#xD;
&#xD;
          -  First degree relative or more than one relative with PD&#xD;
&#xD;
          -  Diagnosis of dementia or MMSE &lt; 25&#xD;
&#xD;
          -  Diagnosis of major depression or psychosis (DSM-V criteria)&#xD;
&#xD;
          -  Any of the following within the previous 2 months: hospital admission, narcosis or&#xD;
             sedation, abdominal trauma&#xD;
&#xD;
          -  Primary disease of gastrointestinal tract (exception: chronic gastritis)&#xD;
&#xD;
          -  Previous abdominal or anorectal surgery (causing structural abnormalities of the&#xD;
             intestines)&#xD;
&#xD;
          -  Any of the following within the previous 2 months: gastrointestinal or respiratory&#xD;
             tract infection, food intoxication&#xD;
&#xD;
          -  The use of probiotics or antibiotics within three months prior to FMT&#xD;
&#xD;
          -  Contra-indications for colonoscopy&#xD;
&#xD;
          -  Other immune disorder or clinical immunosuppression&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Any severe comorbidity that might interfere with the study course as determined by the&#xD;
             treating physician&#xD;
&#xD;
          -  Pregnancy or inadequate anti conception for the duration of the trial&#xD;
&#xD;
        Inclusion criteria for donors&#xD;
&#xD;
          -  age 18 - 75 years&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  normal screening protocol, including screening for infectious diseases, according to&#xD;
             the recommendations of the Superior Health Council of Belgium concerning the safety&#xD;
             and quality of fecal transplantation in humans&#xD;
&#xD;
        Exclusion criteria for donors&#xD;
&#xD;
          -  presence of gastrointestinal symptoms&#xD;
&#xD;
          -  gastro-intestinal or other important comorbidity&#xD;
&#xD;
          -  obesity or metabolic syndrome&#xD;
&#xD;
          -  history of malignancy both gastrointestinal or systemic&#xD;
&#xD;
          -  presence of known colon polyps&#xD;
&#xD;
          -  recent placing of piercings/tattoos&#xD;
&#xD;
          -  sexual risk behaviour&#xD;
&#xD;
          -  antimicrobial therapy 3 months prior to donation&#xD;
&#xD;
          -  living in the same household as a Parkinson's disease patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Santens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University, Ghent University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>January 27, 2023</last_update_submitted>
  <last_update_submitted_qc>January 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Fecal microbiota transplantation</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Gut-brain axis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03808389
org study id: UGent2018/0623
nct id: NCT03808389
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Parkinson's disease (PD) is the second most common neurodegenerative disorder and due to the
      lack of early diagnosis and effective therapy, represents a large burden for our society and
      healthcare system. The last years, it became increasingly apparent that non-motor symptoms,
      including gastrointestinal dysfunction, precede the onset of the typical PD motor symptoms by
      several years. Moreover, emerging evidence suggests that PD, and more specifically the
      aggregation of alpha-synuclein, starts in the gut before spreading to the brain.
      Additionally, recent microbiome studies consistently showed microbiota differences between PD
      patients and healthy controls.

      The ultimate goal of this project is to address the impact of gut dysbiosis and the
      restoration of gut homeostasis by fecal microbiota transplantation (FMT) on the development
      and progression of PD. We will identify PD-specific changes in microbiota composition and gut
      inflammation and determine the effect of a 'microbiome-reset' approach through FMT in PD
      patients on the identified changes and more importantly on disease symptoms and progression.
In this study the effects of fecal microbiota transplantation (FMT) on patients with
      Parkinson's disease will be investigated in a double-blind, placebo-controlled randomized
      clinical trial.

      At time of FMT, forty patients will be randomized in a double-blinded fashion to the
      treatment arm (healthy donor stool) or placebo arm (own stool). Transplantation will be
      performed through nasojejunal administration.

      Donors for this study will be recruited from a healthy donor pool who will donate stool after
      clearance of a strict inclusion protocol which will assess the presence of any infectious
      diseases. Donor stool will be frozen and stored until day of FMT.

      Participants will be screened for relevant inclusion and exclusion criteria and will have to
      sign an informed consent before admission to the study.

      Prior and on a regular basis following the FMT participants will be evaluated through
      neurological clinical examination and standardized clinical scoring scales including
      MDS-UPDRS, PDQ-39, NMSS and MoCA. Stool samples will be taken regularly and stored at -80°C
      for microbiome analysis. Blood will be collected for determining relevant markers. All
      participants will also undergo sampling for oral and nasal microbiome. Follow-up will
      continue for a total duration of one year.

      Prior to FMT, all participants will undergo a colonoscopy to exclude contra-indications for
      FMT and to collect mucosa-adherent microbial samples and gastrointestinal tissue biopts. This
      colonoscopy will be repeated once, one year following the FMT.

      The primary endpoint in this study will be a change in clinical status measured through the
      MDS-UPDRS. Additionally, motor and non-motor symptoms will be correlated with serum markers
      of inflammation and gut and central nervous system barrier function, microbiota changes and
      gastrointestinal biopsy analysis of inflammation.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: 40 patients with Parkinson's disease (Hoehn & Yahr score 2-3) will be randomly allocated (20 vs. 20) to either fecal microbiota transplantation with donor stool or autologous fecal microbiota transplantation (= own stool).
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Changes in clinical symptoms as scored on the MDS-UPDRS (Movement Disorder Society - Unified Parkinson's Disease Rating Scale)
time frame: 3 months, 6 months, 12 months
description: The MDS-UPDRS (Movement Disorder Society - Unified Parkinson's Disease Rating Scale) has four parts: Part I (non-motor experiences of daily living; 13 items), Part II (motor experiences of daily living; 13 items), Part III (motor examination; 33 scores based on 18 items, several with right, left or other body distribution scores) and Part IV (motor complications; 6 items). Each item has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Part III will be clinically scored in an OFF-medication state. Subscales are analyzed separately.
References:
Goetz, C. et al. Movement Disord 22, 41-47 (2007).
Goetz, C. et al. Movement Disord 23, 2129-2170 (2008).
measure: Changes in non-motors symptoms as scored on the Non-motor symptoms scale for Parkinson's disease (NMSS)
time frame: 3 months, 6 months, 12 months
description: Non-motor symptoms scale for Parkinson's disease (NMSS). Non-motor symptoms are assessed over the last month. Each symptom is scored with respect to:
Severity: 0 = None; 1 = Mild: symptoms present but causes little distress or disturbance to patient; 2 = Moderate: some distress or disturbance to patient; 3 = Severe: major source of distress or disturbance to patient.
Frequency: 1 = Rarely (<1/wk); 2 = Often (1/wk); 3 = Frequent (several times per week); 4 = Very Frequent (daily or all the time).
NMSS contains nine dimensions: cardiovascular (2 items), sleep/fatigue (4 items), mood/cognition (6 items), perceptual problems (3 items), attention/memory (3 items), gastrointestinal (3 items), urinary (3 items), sexual function (2 items), and miscellaneous (4 items).
Subscores are calculated through multiplication of frequency x severity. Total score is calculated by adding all subscores, range 0-360.
Reference: Chaudhuri, K. R. et al. Mov. Disord. 22, 1901-11 (2007).
measure: Changes in quality of life as scored on the Parkinson's Disease Quality of Life Questionnaire (PDQ-39)
time frame: 3 months, 6 months, 12 months
description: Parkinson's Disease Quality of Life Questionnaire. All 39 questions are coded in the same way: 0 = Never; 1 = Occasionally; 2 = Sometimes; 3 = Often; 4 = Always (or cannot do at all, if applicable).
The different dimensions are mobility (10 items), activities of daily living (6 items), emotional well being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items).
Each dimension is calculated as a scale from 0 to 100 (0 = no problem at all; 100 = maximum level of problem). Formula for scoring each dimension = (sum of scores of each question in dimension)/ (4 x number of questions in dimension) x 100.
The Single Index score: PDQ-SI= summing the eight dimensions and then dividing by eight.
Reference: Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. Age Ageing 26, 353-7 (1997).
measure: Changes in cognition as scored on the Montreal Cognitive Assessment (MoCA)
time frame: 3 months, 6 months, 12 months
description: The Montreal Cognitive Assessment (MoCA) assesses several cognitive domains: short-term memory, visuospatial abilities, executive functions, attention, concentration, working memory, language, orientation to time and place. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.
Reference: Nasreddine, Z. et al. J Am Geriatr Soc 53, 695-699 (2005).
measure: Number of participants with a change in required anti-PD symptomatic or levodopa therapy
time frame: 3 months, 6 months, 12 months
measure: Changes in gastrointestinal symptoms as assessed by the Rome IV questionnaire
time frame: 3 months, 6 months, 12 months
description: The Rome IV criteria for functional constipation and irritable bowel syndrome are assessed to evaluate potential change in gastrointestinal symptoms following the fecal microbiota transplantation.
arm group label: Treatment group: Donor FMT
arm group type: Experimental
description: Fecal microbiota transplantation using fecal matter from a healthy donor selected through strict inclusion criteria assessing the presence of any infectious diseases.
arm group label: Control group: Autologous FMT
arm group type: Sham Comparator
description: Fecal microbiota transplantation using the patient's own fecal matter.
intervention type: Other
intervention name: Donor FMT
description: Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
arm group label: Treatment group: Donor FMT
other name: FMT with donor stool
intervention type: Other
intervention name: Autologous FMT
description: Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
arm group label: Control group: Autologous FMT
other name: FMT with own stool
criteria: 
gender: All
minimum age: 50 Years
maximum age: 65 Years
healthy volunteers: No
last name: Patrick Santens, MD, PhD
role: Principal Investigator
affiliation: Ghent University, Ghent University Hospital
facility: 
country: Belgium
responsible party type: Sponsor
mesh term: Parkinson Disease
sharing ipd: No